Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Appl Thromb Hemost ; 28: 10760296221126172, 2022.
Article in English | MEDLINE | ID: mdl-36217728

ABSTRACT

OBJECTIVES: Preeclampsia (PE) is a serious complication of pregnancy. The fibrinolytic system play crucial roles regarding placentation and evolution of PE. AIM: To study comprehensively components of the fibrinolytic system and fibrin lysability in women with PE. DESIGN AND METHODS: 117 women with PE and matched controls were included. Tissue type plasminogen activator (t-PA), plasminogen, PAI-1, plasmin inhibitor (PI), D-dimer, the fibrinolytic potential of dextran sulphate euglobulin fraction (DEF), PAI-2, polymere PAI-2, fibrin clot lysability, thrombin activatable fibrinolysis inhibitor (TAFI) and fibrinogen were assessed. RESULTS: Women with PE had significantly increased concentrations of t-PA and PAI-1, whereas the plasma concentration of PAI-2 was significantly lower compared to controls, p < 0.0001. Polymere PAI-2 was detected in both groups. DEF, TAFI and fibrinogen were not different between the groups. D-dimer was significantly increased and plasminogen/PI together with fibrin clot lysability time decreased in the PE-group, p = 0.0004 p = 0.04, p = 0.03, p < 0.0001 respectively. CONCLUSION: This study demonstrates that PE is associated with an affected t-PA/PAI-1 system, decreased PAI-2 and increased fibrin lysability. Furthermore, PAI-2 has the potential to polymerize during pregnancy.


Subject(s)
Antifibrinolytic Agents , Carboxypeptidase B2 , Pre-Eclampsia , Thrombosis , Female , Humans , Pregnancy , Dextran Sulfate/pharmacology , Fibrin , Fibrinogen/pharmacology , Fibrinolysis , Plasminogen/pharmacology , Plasminogen Activator Inhibitor 1 , Plasminogen Activator Inhibitor 2/pharmacology , Tissue Plasminogen Activator
SELECTION OF CITATIONS
SEARCH DETAIL
...